SELLAS Life Sciences Group, Inc. cash flow to debt ratio of -2.84K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

SELLAS Life Sciences Group, Inc.'s free cash flow has increased -19.81% from $-35.40M last year to $-28.39M, signaling increasing performance

SELLAS Life Sciences Group, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

SELLAS Life Sciences Group, Inc.'s debt has decreased relative to shareholder equity from 0.11 last year to 0.01 today, signaling strengthened financials

SELLAS Life Sciences Group, Inc. has a net cash position, so leverage is healthy.

SELLAS Life Sciences Group, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

SELLAS Life Sciences Group, Inc. has insufficient data to evaluate this check.

SELLAS Life Sciences Group, Inc.'s short-term assets of $75.21M exceed its short-term liabilities of $7.02M

SELLAS Life Sciences Group, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

SELLAS Life Sciences Group, Inc.'s return on equity of -47.12%, is lower than 15.00%, indicating bad performance

SELLAS Life Sciences Group, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

SELLAS Life Sciences Group, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

SELLAS Life Sciences Group, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

SELLAS Life Sciences Group, Inc. has negative free cash flow, indicating cash burn

SELLAS Life Sciences Group, Inc.'s yearly earnings has increased -13.01% since last year from $-30.88M to $-26.86M, signaling increasing performance

SELLAS Life Sciences Group, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -29.06% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

SELLAS Life Sciences Group, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

SELLAS Life Sciences Group, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

SELLAS Life Sciences Group, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

SELLAS Life Sciences Group, Inc. has insufficient data to evaluate this check.

SELLAS Life Sciences Group, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

SELLAS Life Sciences Group, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

SELLAS Life Sciences Group, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

SELLAS Life Sciences Group, Inc. has insufficient data to evaluate this check.

SELLAS Life Sciences Group, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

SELLAS Life Sciences Group, Inc. has a price-to-book ratio of 17.73x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

SELLAS Life Sciences Group, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue